| Li, Zhanguo |
NCT05262686: Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 10 | RoW | Belimumab, Interleukin-2, Recombinant Human interleukine-2 | Peking University People's Hospital | Systemic Lupus Erythematosus | 06/23 | 06/23 | | |
NCT06145893: A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease |
|
|
| Recruiting | 3 | 162 | RoW | Hemay005, Mufemilast, Phosphodiesterase 4 (PDE4) inhibitors, Placebo | Ganzhou Hemay Pharmaceutical Co., Ltd | Behçet's Disease | 11/24 | 03/25 | | |
NCT05339217: Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 60 | RoW | Telitacicept, RC-18, Interleukin-2, Recombinant Human interleukine-2 | Liu Tian | Systemic Lupus Erythematosus | 07/25 | 07/25 | | |
| Enrolling by invitation | 3 | 240 | RoW | Interleukin-2, Recombinant Human Interleukin-2 | Peking University People's Hospital | Dermatomyositis | 09/25 | 09/26 | | |
NCT05796206: A Clinical Study of MIL62 in Systemic Lupus Erythematosus |
|
|
| Recruiting | 2/3 | 200 | RoW | MIL62, placebo | Beijing Mabworks Biotech Co., Ltd. | Systemic Lupus Erythematosus | 02/26 | 07/26 | | |
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. |
|
|
| Recruiting | 2 | 144 | RoW | Iguratimod, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Primary Sjögren Syndrome | 04/22 | 06/22 | | |
NCT05087589: Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome |
|
|
| Recruiting | 2 | 10 | RoW | Tofacitinib | Peking University People's Hospital | Primary Sjögren's Syndrome | 01/23 | 10/23 | | |
NCT05400889: Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies |
|
|
| Recruiting | 2 | 10 | RoW | tofacitinib, Baricitinib | Peking University People's Hospital | Idiopathic Inflammatory Myopathies | 03/23 | 06/23 | | |
NCT05576597: Effect of Butyrate Supplement on Rheumatoid Arthritis |
|
|
| Completed | 2 | 30 | RoW | Sodium Butyrate | Peking University People's Hospital | Rheumatoid Arthritis | 10/23 | 06/24 | | |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
NCT04077684: Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial |
|
|
| Completed | 2 | 152 | RoW | Interleukin-2, Human recombinant IL-2 | Peking University People's Hospital | Systemic Lupus Erythematosus | 03/24 | 08/24 | | |
| Recruiting | 2 | 190 | Europe, Japan, US, RoW | Obexelimab, Placebo | Zenas BioPharma (USA), LLC | Systemic Lupus Erythematosus | 06/26 | 09/26 | | |
NCT06504420: The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study |
|
|
| Not yet recruiting | 2 | 70 | NA | Sirolimus, Placebo | Peking University People's Hospital | Primary Antiphospholipid Syndrome | 12/26 | 12/27 | | |
NCT06794008: BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases |
|
|
| Recruiting | 2 | 50 | RoW | BCMA-CD19 CAR-T therapy | Peking University People's Hospital | Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis, IgG4-Related Diseases, Antiphospholipid Syndrome, Acquired Thrombotic Thrombocytopenic Purpura, Behcet Disease, Sjogren Syndrome | 12/27 | 12/27 | | |
NCT05814939: Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. |
|
|
| Completed | 2 | 180 | RoW | VC005 tablets, Tofacitinib Citrate Tablets, VC005 Tablets Placebo | Jiangsu vcare pharmaceutical technology co., LTD | Active Ankylosing Spondylitis | 05/24 | 05/24 | | |
NCT05605665: Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome |
|
|
| Completed | 1/2 | 30 | RoW | low-dose interleukin-2, Recombinant Human Interleukin-2, rapamycin, sirolimus | Peking University People's Hospital | Sjögren's Syndrome | 12/23 | 03/24 | | |
NCT04457856: A Study of TJ003234 in Rheumatoid Arthritis Patients |
|
|
| Recruiting | 1 | 63 | RoW | TJ003234 injection | I-Mab Biopharma Co. Ltd. | Rheumatoid Arthritis | 03/23 | 03/23 | | |
NCT06340490: A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) |
|
|
| Not yet recruiting | 1 | 24 | RoW | RJMty19 (CD19-CAR-DNT cells), Fludarabine, Cyclophosphamide | Guangdong Ruishun Biotech Co., Ltd, RenJi Hospital, Peking University People's Hospital, Changhai Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Systemic Lupus Erythematosus | 12/26 | 12/27 | | |
NCT05245448: Tetrandrine in the Treatment of Rheumatoid Arthritis |
|
|
| Not yet recruiting | N/A | 240 | RoW | Tetrandrine, Placebo | Peking University People's Hospital | Rheumatoid Arthritis | 10/23 | 03/24 | | |
NCT05240859: Real World Study of a Adalimumab Biosimilar (Geleli) in Rheumatoid Arthritis |
|
|
| Not yet recruiting | N/A | 1600 | RoW | Geleli | Peking University People's Hospital | Rheumatoid Arthritis | 02/24 | 08/24 | | |
